This notion is further supported by recent findings from the SURMOUNT‐OSA trial, which reported that tirzepatide—a dual GLP‐1/GIP receptor agonist—significantly improved OSA severity alongside weight loss and cardiometabolic benefits [18]. This evidence concerns the gene GCG and obstructive sleep apnea syndrome.